• Citer

Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology.

par Fumagalli, Debora ;Blanchet-Cohen, Alexis;Brown, David;Desmedt, Christine ;Gacquer, David ;Michiels, Stefan ;Rothé, Françoise ;Majjaj, Samira ;Salgado, Roberto;Larsimont, Denis ;Ignatiadis, Michail ;Maetens, Marion M. ;Piccart-Gebhart, Martine ;Detours, Vincent ;Sotiriou, Christos ;Haibe-Kains, Benjamin
Référence BMC genomics, 15, 1, page (1008)
Publication Publié, 2014-11-21

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Microarrays have revolutionized breast cancer (BC) research by enabling studies of gene expression on a transcriptome-wide scale. Recently, RNA-Sequencing (RNA-Seq) has emerged as an alternative for precise readouts of the transcriptome. To date, no study has compared the ability of the two technologies to quantify clinically relevant individual genes and microarray-derived gene expression signatures (GES) in a set of BC samples encompassing the known molecular BC's subtypes. To accomplish this, the RNA from 57 BCs representing the four main molecular subtypes (triple negative, HER2 positive, luminal A, luminal B), was profiled with Affymetrix HG-U133 Plus 2.0 chips and sequenced using the Illumina HiSeq 2000 platform. The correlations of three clinically relevant BC genes, six molecular subtype classifiers, and a selection of 21 GES were evaluated.